|
2007 Conference Publication Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant PatientsHourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Ghandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. American Transplant Congress 2007, USA, 5-9 May 2007. UK: Wiley-Blackwell Publising Ltd.. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2007 Conference Publication Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II studyTrappe, R., Choquet, S., Oertel, S., LeBlond, V., Ekman, T., Sender, M., Mollee, P, Reinke, P., Lehmkuhl, H., Hummel, M., Jonas, S., Neuhaus, R., Salles, G., Morschhauser, F., Jaccard, A., Anagnostopoulos, I., Raphael, M. and Riess, H. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Annual American Transplant Congress, San Francisco, CA, United States, 5 - 9 May 2007. Malden, MA, United States: Wiley-Blackwell Publishing. doi: 10.1111/j.1600-6143.2007.01811.x |
|
2006 Conference Publication Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patientsGill, Saar, Lane, Steven, Crawford, Julie, Mollee, Peter, Marlton, Paula, Cull, Gavin, Prince, Miles and Seymour, John Francis (2006). Prolonged hematologic toxicity from the Hyper-CVAD regimen; manifestations, frequency, and natural history in a cohort of 125 consecutive patients. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.v108.11.2441.2441 |
|
2006 Conference Publication Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).Lane, SW, Saal, R, Mollee, P, Grigg, A, Taylor, K, Seymour, JF, Kennedy, G, Williams, B, Jones, M, Grimmett, K, Griffiths, V, Gill, D, Hourigan, M and Marlton, P (2006). Real-time quantitative polymerase chain reaction (RQ-PCR) monitoring of minimal residual disease (MRD) in core binding factor acute myeloid leukaemia (CBF AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. |
|
2006 Conference Publication Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseasesTate, J.R., Mollee, P., Carter, A. and Gill, D. (2006). Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases. 58th Annual Meeting of the American Association of Clinical Chemistry, Chicago, IL, United States, 23-27 July 2006. Washington, DC, United States: American Association for Clinical Chemistry. |
|
2006 Conference Publication Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).Lane, SW, Saal, R, Negus, S, Mollee, P, Mather, M, Gill, D, Mills, AK, Bird, RJ, Hourigan, MJ, Jones, M and Marlton, P (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando Fl, Dec 09-12, 2006. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2005 Conference Publication Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)Lane, Steven W., Mollee, Peter N., Bird, Robert, Porceddu, Sandro and Gill, Devinder (2005). Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL). 47th ASH Annual Meeting, Atlanta, GA United States, 10-13 December 2005. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v106.11.4993.4993 |
|
2005 Conference Publication Falsely low serum free light chain concentration in patients with monoclonal light chain diseasesMollee, Peter, Tate, Jill, Dimeski, Goce and Gill, Devinder (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. 47th ASH Annual Meeting, Atlanta, GA United States, 10-13 December 2005. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v106.11.5077.5077 |
|
2005 Conference Publication Falsely low serum free light chain concentration in patients with monoclonal light chain diseasesMollee, Peter, Tate, Jill, Dimeski, Goce and Gill, Devinder (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. |
|
2005 Conference Publication Accelerated delivery of Rituximab is safe on an out-patient basis.Middleton, HJ, Mollee, P, Bird, R, Mills, AK, Marlton, P and Gill, D (2005). Accelerated delivery of Rituximab is safe on an out-patient basis.. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 10-13, 2005. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2005 Conference Publication Falsely low serum free light chain concentration in patients with monoclonal light chain diseasesTate, J.R., Mollee, P., Dimeski, G. and Gill, D. (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. Annual Meeting of the American Association Clinical Chemistry, Orlando, FL, United States, 24-28 July 2005. Washington, DC, United States: American Association for Clinical Chemistry. |
|
2005 Conference Publication Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.Lane, SW, Crawford, J, Kenealy, M, Cull, G, Seymour, JF, Prince, M, Marlton, P, Gill, D and Mollee, PN (2005). Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V106.11.4274.4274 |
|
2005 Conference Publication Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)Lane, S. W., Mollee, P. N., Bird, R., Porceddu, S. and Gill, D. (2005). Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL). 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. |
|
2005 Conference Publication A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphomaKuruvilla, J., Mollee, P., Song, K., Zaretsky, Y., Panzarella, T., McCrae, J., Nagy, T., Crump, M. and Keating, A. (2005). A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 9 -11 June 2005. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdi582 |
|
2004 Conference Publication Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimenMills, AK, Gibbs, S, Keane, C, Mollee, P, Grimmett, K, Van Kuilenburg, R, Saal, R, Gill, D, Prince, HM, Seymour, JF and Marlton, P (2004). Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimen. 46th Annual Meeting of the American-Society-of-Hematology, San Diego Ca, Dec 04-07, 2004. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2004 Conference Publication Serum free light chain ratios do not detect relapse in some patients with intact immunoglobulin myeloma post autologous peripheral blood stem cell transplantation.Tate, JR, Mollee, P and Gill, D (2004). Serum free light chain ratios do not detect relapse in some patients with intact immunoglobulin myeloma post autologous peripheral blood stem cell transplantation.. 56th Annual Meeting of the American-Association-for-Clinical-Chemistry, Los Angeles Ca, Jul 25-29, 2004. WASHINGTON: AMER ASSOC CLINICAL CHEMISTRY. |
|
2003 Conference Publication The impact of the hyper-CVAD chemotherapy regimen on the ability to mobilize peripheral blood stem cells (PBSC) in patients with hematological malignancies.Mollee, PN, Mills, AK, Grimmett, K, Van Kuilenburg, R, Saal, RJ, Gill, D, Cobcroft, R and Marlton, P (2003). The impact of the hyper-CVAD chemotherapy regimen on the ability to mobilize peripheral blood stem cells (PBSC) in patients with hematological malignancies.. 45th Annual Meeting of the American-Society-of-Hematology, San Diego, CA, United States, 6-9 December 2003. Washington, DC, United States: American Society of Hematology. |
|
2002 Conference Publication Autologous stem cell transplantation (ASCT) for relapsed/refractory follicular large cell lymphoma (FLCL).Mollee, P, Song, K, Keating, A, Tsang, R and Crump, M (2002). Autologous stem cell transplantation (ASCT) for relapsed/refractory follicular large cell lymphoma (FLCL).. 44th Annual Meeting of the American-Society-of-Hematology, Philadelphia Pennsylvania, Dec 06-10, 2002. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2002 Conference Publication Effect of gemcitabine, dexamethasone and cisplatin salvage chemotherapy (GDP) on peripheral blood stem cell (PBSC) mobilization in patients with lymphoma.Mollee, P, Nagy, T, Saragosa, R, Turner, R, Keating, A and Crump, M (2002). Effect of gemcitabine, dexamethasone and cisplatin salvage chemotherapy (GDP) on peripheral blood stem cell (PBSC) mobilization in patients with lymphoma.. 44th Annual Meeting of the American-Society-of-Hematology, Philadelphia Pennsylvania, Dec 06-10, 2002. WASHINGTON: AMER SOC HEMATOLOGY. |
